Constantinos Panagos - Mar 17, 2022 Form 3 Insider Report for IQVIA HOLDINGS INC. (IQV)

Role
President, Research & Development Solutions Power of Attorney
Signature
/s/ Matthew Gilmartin, Attorney-in-Fact for Constantinos Panagos
Stock symbol
IQV
Transactions as of
Mar 17, 2022
Transactions value $
$0
Form type
3
Date filed
3/17/2022, 05:05 PM
Next filing
Nov 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IQV Common Stock 37.2K Mar 17, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IQV Stock Appreciation Right Mar 17, 2022 Common Stock 2.85K $95.23 Direct
holding IQV Stock Appreciation Right Mar 17, 2022 Common Stock 7.68K $131.82 Direct
holding IQV Stock Appreciation Right Mar 17, 2022 Common Stock 11.2K $161.70 Direct F2
holding IQV Stock Appreciation Right Mar 17, 2022 Common Stock 6.68K $183.82 Direct F3
holding IQV Stock Appreciation Right Mar 17, 2022 Common Stock 7.28K $250.43 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amount includes 4,090 RSUs granted on November 1, 2018 which will vest on November 1, 2022, 6,253 RSUs granted on February 11, 2020 which will vest in two annual installments beginning on February 11, 2023, 1,114 RSUs granted on February 9, 2021 which will vest in two annual installments beginning on February 9, 2023, 10,700 RSUs granted on February 9, 2021 which will vest in two annual installments beginning on February 9, 2023, 1,956 RSUs granted on February 10, 2022 which will vest in three annual installments beginning on February 10, 2023 and 3,912 RSUs granted on February 10, 2022 which will vest in two annual installments beginning on February 10, 2024.
F2 This stock appreciation right remains outstanding under the grant; 7,468 of which are currently vested; and 3,734 of which will vest on February 11, 2023.
F3 This stock appreciation right remains outstanding under the grant; 2,225 of which are currently vested; and 4,450 of which will vest in two annual installments beginning on February 9, 2023.
F4 This stock appreciation right vests in three annual installments beginning on February 10, 2023.

Remarks:

President, Research & Development Solutions Power of Attorney